Rebecca Simmons COO

52North (Cambridge, UK) is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds innovative diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company.

Therapeutic: Oncology; Digital Health

Stav Tori CEO

Coming soon.

Therapeutic: In progress

Daniel Gelman CEO

Aufero Medical (London, Ontario, Canada) is transforming cardiac ablation with TruContact, a robotic tool enhancing catheter stability during ablation therapy for atrial fibrillation and heart rhythm disorders. Unstable catheters, an issue in half of procedures, reduce success rates. TruContact uses robotics and machine learning to ensure catheter stability, delivering high-quality ablations and empowering physicians of all skill levels. Partnered with leading EP market players, Aufero has raised over $1M, generated robust preclinical data, and secured strategic partnerships for global market expansion.

Therapeutic: Cardiovascular & Electrophysiology

Randy Pritchard CEO

Axena Health (Auburndale, MA, USA) is a commercial-stage medical device company dedicated to improving the lives of women through clinically proven non-surgical treatments for pelvic floor disorders.  Axena Health’s product, the Leva® Pelvic Health System, offers a novel, clinically proven, at-home treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), conditions that currently lack effective, scalable non-surgical treatment options.  The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies published in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG). 

Therapeutic: Women’s Health

Ilan Uchitel CEO

CAPS Medical (Israel) has developed a proprietary PlasmaSure technology that uses Non Thermal Plasma (NTAP) to selectively target tumors through minimally invasive procedures. The PlasmaSure system uses existing minimally invasive tools and robotic systems, targeting a $100B TAM. CAPS effectively eliminates cancerous cells while preserving healthy tissue, allowing treatments to move from the operating room into a doctor's clinic. The technology is clinically tested and applicable to wide range of tumors.

Therapeutic: Oncology

Coming soon.

Therapeutic: Coming soon.

Jason Mowles CEO

CergenX (Cork, Ireland) is an AI-driven neurotechnology company redefining how early brain health is assessed. Built on decades of groundbreaking neonatal brain research, its proprietary AI platform transforms complex physiological data into real-time, expert-level insights and accelerates the development of high-impact clinical solutions. The company’s first product, Wave, is an FDA-designated breakthrough device that identifies newborns at highest risk of brain injury. Delivering expert-informed brain function assessments at the point of care in under 15 minutes, Wave supports timely intervention and improved outcomes.

Therapeutic: Artificial Intelligence; Neonatal Neurology

Pim van Wesel CEO

CaverSTIM (Lausanne, Switzerland) is a novel implantable device able to restore natural penile erection by neuromodulation.

Therapeutic: Neuromodulation-Neurostimulation; Urology, Sexual Function

David Constantine Co-Founder & CEO

Coming soon.

Therapeutic category: In progress

Dom Messerli President & CEO

Based in Providence, Rhode Island, Lenoss Medical is a medical device company dedicated to the design, development and commercialization of a novel biological implant and associated delivery instrumentation for the treatment of painful vertebral compression fractures. Lenoss Medical developed the only fully biological solution for treating VCFs. The OsteoPearl Biological Augmentation is a minimally invasive spinal implant designed to stabilize the spinal fracture and create an environment for restoration and healing. Immediate stability is created by the structural matrix, introducing both osteoinductive and osteoconductive properties. Placing Natural bone where More bone is needed most.

Therapeutic: Pain management; Orthopedics-Spine

Xiaopei Huang CEO

We are a medical device company developing next-generation SPECT imaging systems with unmatched sensitivity and accuracy. Our technology is designed to advance radiopharmaceutical development and molecular imaging for clinical use, enabling faster, higher-resolution scans with improved quantification. By addressing limitations of current imaging systems, we aim to support the growing needs of clinicians and researchers in neurology, oncology, and theranostics. Our mission is to accelerate drug development and improve patient outcomes through innovative molecular imaging solutions.

Therapeutic: Diagnostics

Esther Novosel CEO

Neuroloop (Freiburg, Germany) will develop & market a technology platform based on thin-film technology for controllable selective stimulation of the vagus nerve. Our Agenda is driven by 3 Key projects: 1. baroloop®: VNS stimulation to lower Blood pressure in patients with true resistant Hypertension. 2. VNS stimulation to address an anti-inflammatory indication (in cooperation with Merck KGaA) 3. Continuous platform development: closed loop, new sensors, remote monitoring & programming. For baroloop we are currently running a multi-center approval trial for CE market.

Therapeutic: Neuromodulation-neurostimulation; Hypertension

Lloyd Diamond CEO

EndoZip, World’s First Automated Endoscopic Treatment for Obesity from Nitinotes Surgical (Ceasarea, Israel).

Therapeutic: Obesity

Ze'ev Dvashi CEO

ClearPlasma (Nazareth, Israel) is a groundbreaking blood filtration device that removes plasminogen from plasma prior to transfusion—offering a novel, clinically validated solution to improve clot stability, reduce bleeding, and save lives in trauma, surgery, and critical care settings.

Therapeutic: Emergency care to treat massive blood loss

James Bowman CEO

Coming soon.

Therapeutic: Coming soon.

Allan Böhm Chief Executive & Medical Officer

Seerlinq (Slovakia, Bratislava) is the world’s first certified medical device enabling non-invasive, home-based monitoring of cardiac filling pressure—an essential parameter in managing heart failure. By detecting deterioration early, Seerlinq’s telemonitoring solution reduces heart failure hospitalizations by over 75%, addressing a global burden of more than 10 million admissions and $100 billion in annual healthcare costs.

Therapeutic: Remote Patient Monitoring; Heart Failure Diagnostics, Telemonitoring, Precision Medicine

Thomas Arnold CEO

Coming soon.

Therapeutic: Coming soon.

Mano Thubrikar President & Founder

Our Company developed the Optimum Transcatheter Aortic Valve and delivery catheter for aortic stenosis patients. Optimum TAV is a short, self-expanding valve with preclinical durability matching surgical valves. It avoids tissue damage from balloon-expansion and allows unrestricted coronary access. 12 patients implanted in Europe have great outcomes out to 3.5 years. Our FIH patient in Brazil is at 7 years post-implant. Increasingly, younger patients with current TAVR valves require Redo-TAVR. Optimum TAV could completely avoid or delay Redo-TAVR for years.

Therapetic: Interventional; Cardiovascular

Thomas Arnold CEO

ViCentra (The Netherlands - Utrecht) is transforming diabetes care with Kaleido, the smallest and lightest insulin patch pump system in its class. It’s a next-generation insulin pump system engineered for today’s users and tomorrow’s healthcare models. Kaleido delivers premium, flexible, and human-first diabetes technology designed to outperform outdated, one-size-fits-all solutions with a seamless blend of performance, lifestyle integration, and user satisfaction.

Therapeutic: Diabetes management; Insulin delivery system; Medical devices – Continuous Subcutaneous Insulin Infusion (CSII) systems